Registry for Participants With Short Bowel Syndrome
This is a global prospective, observational, multi-center registry to evaluate the long-term safety profile for participants with short bowel syndrome (SBS) who are treated with teduglutide in a routine clinical setting. The registry will also evaluate the long-term clinical outcomes in participants with SBS. SBS participants treated and not treated with teduglutide will be enrolled.
- Short Bowel Syndrome
- Eligible Ages
- All ages
- Eligible Genders
- Accepts Healthy Volunteers
- Male and female participants, of any age, with a diagnosis of short bowel syndrome (SBS). 2. Signed informed consent and medical records release by the participant or a legally acceptable representative 3. Participants who have never received teduglutide treatment must be on parenteral nutrition (PN)/intravenous (IV) fluids support for at least 6 months at the time of enrollment.
- Participants currently participating in a blinded clinical trial or their extension studies. 2. Participants who have never been on PN/IV support. 3. Participants who are currently or previously exposed to any Glucagon-like peptide 2 (GLP-2) analogs other than teduglutide.
- Study Type
- Observational [Patient Registry]
- Observational Model
- Time Perspective
|Teduglutide treated||SBS participants who have been treated with teduglutide.|
|Non-teduglutide treated||SBS participants who have not been treated with teduglutide.|
Study ContactShire Contact
28-MAY-2021: Enrollment of new Teduglutide treated adult participants into this study continues according to discretion and availability of sites during the COVID-19 situation, however, enrollment of untreated adult participants and pediatrics patients was stopped on the 30th April 2021 as the targets in these cohorts had been met. Enrollment of new Teduglutide treated adult participants is expected to be prolonged until 2022.